DexCom, Inc. logo
DexCom, Inc. (DXCM)
Compare

DexCom, Inc. (DXCM) Average EV/Assets Ratio

EV/Assets Ratio

The current ev/assets ratio for DexCom, Inc. (DXCM) is 4.53x as of Wednesday, June 10, 2026, shown against its trailing averages.

Average EV/Assets Ratio Chart

DXCM EV/Assets Ratio Averages

EV/ASSETS RATIO CURRENT

4.53x

EV/ASSETS RATIO TTM

4.23x

EV/ASSETS RATIO 3Y

5.88x

EV/ASSETS RATIO 5Y

7.47x

EV/ASSETS RATIO 10Y

9.24x

EV/ASSETS RATIO 15Y

11.99x

EV/ASSETS RATIO 20Y

10.48x

About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

San Diego, CA
10,200 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Jacob Steven Leach